COMUNICADO: Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics

Source Summary

NEWS AKTUELL // Aachen, Germany, 16 July 2026 – Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients.